Introduction {#s01}
============

Individuals with biallelic mutations in the *BLM* gene are affected by Bloom syndrome (BS), a heritable condition associated with developmental abnormalities and susceptibility to a range of malignancies at an early age ([@bib21]). The *BLM* gene product is a helicase of the RECQ family with roles in DNA replication and repair. BLM protein acts at several steps of the homologous recombination (HR) pathway for DNA double-strand break (DSB) repair ([@bib42]). First, BLM, along with the endonuclease Dna2, contributes to resection of DNA DSBs to generate a single-stranded intermediate that is bound by replication protein A (RPA) and RAD51 ([@bib27]; [@bib55], [@bib56]). The RAD51 nucleoprotein filament then pairs with matching sequence in a homologous DNA template, leading to strand invasion and creation of a "D-loop" structure. This process can be inhibited by BLM, representing a potential anti-recombinogenic effect of the protein ([@bib68]; [@bib32]; [@bib73]; [@bib4]; [@bib10]). After resynthesis of DNA across the break site, BLM resolves heteroduplex recombination intermediates by dissolving Holliday junctions, restoring separate DNA duplexes ([@bib73]). The ability of BLM to dissolve Holliday junctions limits the frequency of genetic exchanges between homologous sequences during HR. This is consistent with a marked increase in sister chromatid exchanges (SCEs) in BS cells ([@bib15]; [@bib32]).

The ability of BLM to limit crossover resolution of HR intermediates has been suggested to represent its key activity in limiting genomic instability ([@bib46]). According to this model, the absence of BLM leads to an excessive number of loss-of-heterozygosity events owing to increased crossover recombination, which leads to malignancy. BS cells also show an increase in chromosome breaks and rearrangements, potentially indicating that BLM provides one or more additional repair activities ([@bib19]). This activity may be related to the pro-recombinogenic role of BLM during DSB resection or an anti-recombinogenic effect around the time of D-loop formation.

In this study, we use a genetic approach to test whether pro- or anti-recombinogenic activities of BLM are most relevant for maintenance of genomic integrity in mammalian cells. We find that BLM contributes significantly to genomic instability in cells in which key HR factors are missing, suggesting that the anti-recombinogenic role of BLM has the potential to exert a significant influence on the efficiency of HR in cancer cells. BLM appears to exert this effect by displacing RAD51 from resected DNA intermediates in a process that is dependent on BLM helicase activity but does not require association with DNA topoisomerase IIIα.

Results {#s02}
=======

Ablation of *Blm* rescues genomic instability and cell survival in *Brca1*^Δ11/Δ11^ cells {#s03}
-----------------------------------------------------------------------------------------

BLM has been shown to act with the endonuclease Dna2 to promote formation of 3′ single-stranded overhangs at DSB sites ([@bib27]; [@bib55], [@bib56]). This process contributes to the efficiency of HR; however, the exonuclease Exo1 can perform a similar function in mammalian cells. To evaluate the importance of BLM in generating 3′ single-stranded regions at DSBs, we used mice with conditional deletion of *Blm* in the B lymphocyte lineage, crossed to *Trp53bp1^−/−^* mice ([Fig. 1, A and B](#fig1){ref-type="fig"}; and Fig. S1 A; [@bib59]; [@bib72]; [@bib18]). *Blm*^Δ/Δ^ cells showed an increased frequency of chromosome aberrations after exposure to either olaparib or mitomycin C, which induce DSBs in dividing cells. *Trp53bp1^−/−^* mice lack 53BP1, a negative regulator of DSB resection ([@bib12]; [@bib16]; [@bib28]). We reasoned that increased formation of 3′ single-stranded overhangs at DSBs in *Trp53bp1^−/−^* mice might rescue genomic instability arising from loss of the DSB resection activity of BLM. *Blm*^Δ/Δ^;*Trp53bp1*^−/−^ cells showed chromosome instability equivalent to *Blm*^Δ/Δ^;*Trp53bp1*^+/+^ cells, indicating that removing a barrier to resection is not sufficient to substitute for BLM in the early stages of HR. On the other hand, *Brca1*^Δ11/Δ11^;*Blm*^Δ/Δ^ cells showed a frequency of chromosome aberrations that was significantly lower than that seen in *Brca1*^Δ11/Δ11^ cells ([Fig. 1, A and B](#fig1){ref-type="fig"}; and Fig. S1, A and B). *Brca1*^Δ11/Δ11^ cells normally have a high level of genomic instability that arises at least in part because of a failure to perform HR ([@bib53]; [@bib76]; [@bib12]). This genomic instability is dependent on the presence of BLM, indicating that BLM contributes to the defect in HR in *Brca1*^Δ11/Δ11^ cells.

![**Ablation of *Blm* rescues genomic instability, T cell development, and poly (ADP-ribose) polymerase inhibitor sensitivity in *Brca1^Δ11/Δ11^* cells.** (A) Metaphase spreads from primary mouse B lymphocyte cells stained with DAPI and Cy3-labeled telomeric probe. The arrows point to chromatid breaks, closed arrowheads point to chromosome breaks, and open arrowheads point to radial chromosomes. Bars, 10 µm. (B) Quantification of genomic instability in metaphase spreads after 2 µM overnight treatment with the poly (ADP-ribose) polymerase inhibitor olaparib. CSB, chromosome breaks; CTB, chromatid breaks. (C) Flow cytometry data from primary T lymphocyte cells from mice of indicated genotypes stained with CD4 and CD8 antibodies. (D) Quantification of CD4^−^ CD8^−^ double-negative T cells. (E) Clonogenic survival assay after BLM knockdown in WT and BRCA1^Δ11/Δ11^ cells with no treatment (NT) and chronic treatment with 100 nM Olaparib (OLA), a poly (ADP-ribose) polymerase inhibitor. (F) Quantification of clonogenic survival assay after shBLM in WT and BRCA1^Δ11/Δ11^ MEFs. Graphs represent mean ± SD of three independent experiments.](JCB_201703144_Fig1){#fig1}

We used two assays to test whether the different levels of genomic instability in *Brca1*^Δ11/Δ11^, *Blm*^Δ/Δ^, and *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ cells affected their ability to divide and proliferate. First, we targeted *Brca1* in the thymus using a conditional knockout approach to produce *Brca1*^Δ11/Δ11^ thymocytes ([@bib29]). These *Brca1*^Δ11/Δ11^ thymocytes show a partial developmental block at the transition from the CD4^−^ CD8^−^ "double negative" stage to the CD4^+^ CD8^+^ "double positive" stage, corresponding to apoptosis induced by genomic instability ([Fig. 1, C and D](#fig1){ref-type="fig"}; [@bib47]). In contrast, *Brca1*^Δ11/Δ11^;*Blm*^Δ/Δ^ cells showed a significantly reduced block at the double-negative to double-positive transition. The improved DNA repair seen in *Brca1*^Δ11/Δ11^;*Blm*^Δ/Δ^ cells relative to *Brca1*^Δ11/Δ11^ cells is therefore relevant in a physiological setting. Second, we used a colony forming assay to measure the ability of WT and *Brca1*^Δ11/Δ11^ mouse embryonic fibroblast (MEF) cells to proliferate in vitro after exposure to olaparib ([Fig. 1 E](#fig1){ref-type="fig"}). Whereas *Brca1*^Δ11/Δ11^ cells stably expressing a control shRNA showed substantial hypersensitivity to olaparib, knockdown of *BLM* afforded a significant rescue of cell survival ([Fig. 1 F](#fig1){ref-type="fig"}). BLM therefore contributes to cell death in *Brca1-*deficient cells, in a manner that correlates with improved DSB repair.

Enhanced RAD51 stability at DNA break sites and HR in *Brca1*^Δ11/Δ11^ cells after deletion of *Blm* {#s04}
----------------------------------------------------------------------------------------------------

To understand how BLM impacts DNA repair in *Brca1*^Δ11/Δ11^ cells, we measured nuclear ionizing radiation--induced foci (IRIF) of RAD51, which mark sites of HR-mediated DNA repair. *Brca1*^Δ11/Δ11^ cells are defective for IRIF of RAD51 ([@bib6]; [@bib35]), but we found that the proportion of cells exhibiting RAD51 foci was equivalent to WT in *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ B cells ([Fig. 2, A and B](#fig2){ref-type="fig"}). RAD51 foci were also observed in *Brca1*^Δ11/Δ11^ MEFs after shRNA-mediated knockdown of BLM, whereas cells expressing control shRNA showed a defect in RAD51 foci formation ([Fig. 2, C--E](#fig2){ref-type="fig"}). BLM therefore appears to limit RAD51 assembly at DSBs in *Brca1*^Δ11/Δ11^ cells. Several factors that regulate the assembly and recruitment of RAD51 at break sites have also been shown to regulate RAD51-mediated protection of DNA replication forks ([@bib61]; [@bib30]; [@bib43]; [@bib60]). Using a DNA fiber assay, we found that BLM affected fork protection ([Fig. 2, F and G](#fig2){ref-type="fig"}). As previously reported, *Brca1*^Δ11/Δ11^ cells show a defect in fork protection relative to WT cells after hydroxyurea treatment ([@bib58]). Deletion of *Blm* in *Brca1*^Δ11/Δ11^ cells afforded a partial rescue of fork degradation, which may be related to the ability of BLM to regulate the stability of RAD51 at nascent replication tracts after replication stress.

![**Enhanced Rad51 foci after ablation of *Blm* in *Brca1^Δ11/Δ11^* cells.** (A) Immunofluorescence analysis of Rad51 IRIF in primary B cells from mice of indicated genotypes after IR. (B) Quantification of Rad51 IRIF in primary B cells. (C) Immunofluorescence analysis of Rad51 IRIF in MEF cells with indicated genotypes and shRNA knockdown after IR. (D) Western blot analysis of knockdown efficiency. (E) Quantification of Rad51 IRIF in MEF cells. (F) Experimental scheme and representative images of replication fork degradation analysis after 20 min iododeoxyuridine (IdU) and chlorodeoxyuridine (CldU) labeling, respectively, and exposure to 4 mM hydroxyurea (HU) for 5 h. (G) DNA fiber analysis denoting the mean ratios of CldU/IdU label lengths. Graphs represent mean ± SD of three independent experiments. Bars, 10 µm.](JCB_201703144_Fig2){#fig2}

Next, we used U2OS EJ-DR reporter cells to directly measure the importance of BLM for HR efficiency after siRNA-mediated silencing of *BLM* and *BRCA1* ([Fig. 3, A and B](#fig3){ref-type="fig"}; [@bib7]). Consistent with previous studies and our RAD51 foci results ([Fig. 2, A--E](#fig2){ref-type="fig"}), we observed that the rate of HR was substantially reduced in cells expressing BRCA1^Δ11^. The rate of HR showed a highly significant increase upon codepletion of BLM, however, to a level equivalent to that seen in control cells ([Fig. 3 C](#fig3){ref-type="fig"}). Rates of nonhomologous end joining (NHEJ) were not significantly different in any of the conditions tested ([Fig. 3 D](#fig3){ref-type="fig"}). The differences in cell viability and genomic instability between *Brca1*^Δ11/Δ11^ and *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ cells are therefore correlated with the efficiency of HR.

![**BLM regulates HR in BRCA1^Δ11^ cells.** (A) Western blot analysis of EJ-DR reporter cells transfected with siRNA oligos and/or BRCA1 expression vector or control empty vector (EV). (B) Representative flow cytometry data in the U2OS EJ-DR reporter assay, in which HR-mediated repair of I-SceI--mediated DSBs produces GFP fluorescence and mutagenic NHEJ (mNHEJ) produces DsRed fluorescence. (C) Analysis of relative HR frequency in the U2OS EJ-DR reporter cell line. (D) Analysis of relative mNHEJ frequency in the U2OS EJ-DR reporter cell line. Graphs represent mean ± SD of three independent experiments.](JCB_201703144_Fig3){#fig3}

As a second measure of HR, we assayed the frequency of SCEs, which are formed through crossover HR, in *Brca1*^Δ11/Δ11^, *Blm*^Δ/Δ^, and *Brca1*^Δ11/Δ11^;*Blm*^Δ/Δ^ metaphase chromosome spreads (Fig. S2, A and B). Whereas WT and *Brca1*^Δ11/Δ11^ cells showed an approximately equivalent frequency of SCEs, *Blm*^Δ/Δ^ cells showed an elevated rate of SCEs, consistent with the known role of BLM in promoting noncrossover resolution of Holliday junctions during the final stages of HR ([@bib15]; [@bib73]). *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ chromosomes had fewer SCEs than the high rate seen in *Blm*^Δ/Δ^ cells, but the rate was nonetheless equivalent to or higher than that seen in WT cells.

BLM modifies HR activity in WT cells, but not BRCA1-nullizygous cells {#s05}
---------------------------------------------------------------------

The *Brca1*^Δ11^ allele is considered to be hypomorphic ([@bib23]); hence, we sought to test whether the observed anti-recombinase activity of BLM is also relevant in other BRCA1 mutant cells or in WT cells. Although silencing *Blm* rescues HR in *Brca1*^Δ11/Δ11^ cells, we found that the extent of rescue of RAD51 foci formation was insubstantial in MDA-MB-436 ([@bib22]), a human mammary adenocarcinoma cell line that expresses no BRCA1 protein ([Fig. 4, A and B](#fig4){ref-type="fig"}). We also failed to observe rescue of RAD51 foci formation in U2OS osteosarcoma cells after cosilencing of *BRCA1* and *BLM* using siRNA ([Fig. 4, C and D](#fig4){ref-type="fig"}; and Fig. S2 C). Silencing of *BLM* likewise failed to rescue the HR defect of U2OS EJ-DR reporter cells in which *BRCA1* was knocked down ([Fig. 4 E](#fig4){ref-type="fig"}). Some residual pro-recombinogenic activity provided by the hypomorphic BRCA1^Δ11^ protein that is expressed in *Brca1*^Δ11/Δ11^ cells is therefore necessary for HR even in the absence of *Blm*. BLM appears to regulate the efficiency of HR, and loss of BLM cannot completely substitute for essential HR factors.

![**BLM modifies HR activity in WT cells, but not BRCA1-nullizygous cells.** (A) Immunofluorescence analysis of Rad51 IRIF in MDA-MB-231 (BRCA1 wt) and MDA-MB-436 (BRCA1 mutant) cells after control shRNA or shBLM knockdown. (B) Western blot analysis of BLM knockdown efficiency in MDA-MB-436 cells. (C) Immunofluorescence analysis of Rad51 IRIF in U2OS cells with indicated siRNA knockdown. (D) Western blot analysis of BRCA1 and BLM knockdown efficiency in U2OS cells. (E) Analysis of relative HR and mutagenic NHEJ (mNHEJ) frequency in the EJ-DR U2OS reporter cell line with indicated siRNA knockdown. (F) Analysis of relative HR frequency in the EJ-DR U2OS reporter cell line after overexpression of WT BLM and helicase-dead BLM (BLM^K695A^). Graphs represent mean ± SD of three independent experiments. Bars, 10 µm.](JCB_201703144_Fig4){#fig4}

An anti-recombinogenic activity of BLM has previously been inferred from the high rate of SCEs in BS cells ([@bib15]; [@bib32]). Using the EJ-DR reporter assay, we tested whether overexpression of BLM could suppress HR in *BLM*^+/+^ cells. As has been seen with other mammalian anti-recombinases ([@bib25]; [@bib45]; [@bib62]), overexpression of BLM caused a modest but statistically significant reduction in HR efficiency ([Figs. 4 F](#fig4){ref-type="fig"} and S2 D). Suppression of HR was not observed, however, upon overexpression of a helicase-dead BLM mutant (BLM^K695A^; [@bib10]). BLM therefore has the potential to disrupt HR in WT and *Brca1*^Δ11/Δ11^ cells through its helicase activity. The ability of BLM to dissolve Holliday junctions is further dependent on formation of the multiprotein BTR complex (BLM--topoisomerase III-α--RMI1/2; [@bib50]). To test whether BTR is required for BLM anti-recombinase activity, we measured HR efficiency in cells after siRNA-mediated silencing of *BRCA1* and topoisomerase IIIα (*TOP3A*). In cells expressing mutant BRCA1^Δ11^, silencing *TOP3A* did not rescue the low efficiency of HR ([Fig. 5 A](#fig5){ref-type="fig"}). The anti-recombinase effect of BLM that is active in this assay therefore appears to be independent of the BTR complex. This represents a difference from BLM-mediated dissolution of Holliday junctions, which is dependent on the BTR complex ([@bib73]). NHEJ was not defective in any of the cells tested upon depletion of BLM or TOP3A ([Fig. 5 B](#fig5){ref-type="fig"}).

![**Ablation of *Blm* increases 53BP1 accumulation at DNA break sites in *Brca1^Δ11/Δ11^* cells.** (A) Analysis of relative HR frequency in the EJ-DR U2OS reporter cell line after knockdown of *BRCA1* and *TOP3A* and overexpression of BRCA1^Δ11^. (B) Analysis of relative mutagenic NHEJ (mNHEJ) frequency in the EJ-DR U2OS reporter cell line. (C) Immunofluorescence analysis of 53BP1 IRIF in primary B cells from mice of indicated genotypes after IR. (D) Quantification of 53BP1 IRIF in primary B cells. (E) Immunofluorescence analysis of RPA IRIF in primary B cells from indicated genotypes after IR. (F) Quantification of RPA IRIF in primary B cells. Graphs represent mean ± SD of three independent experiments. Bars, 10 µm.](JCB_201703144_Fig5){#fig5}

The presence of 53BP1 at DSB sites regulates the efficiency of DSB resection and entry into the HR pathway ([@bib16]). 53BP1 limits DSB resection and increases the proportion of DSBs that are repaired by NHEJ. We hypothesized that the different levels of repair seen in *Brca1*^Δ11/Δ11^ and *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ cells may be related to differential 53BP1 recruitment to DSB sites in these cells. We therefore measured the number of 53BP1 foci formed after ionizing radiation (IR) treatment ([Fig. 5 C](#fig5){ref-type="fig"}). Deletion of *Blm* was associated with a slight reduction in 53BP1 foci formation relative to WT, as has been reported previously ([@bib26]). However, *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ cells showed a significantly greater number of 53BP1 foci after IR compared with *Blm*^Δ/Δ^ cells ([Fig. 5, C and D](#fig5){ref-type="fig"}). As the difference in 53BP1 foci was not of great magnitude, we measured class switch recombination (CSR), which is highly sensitive to 53BP1 levels ([@bib48]; [@bib72]). Although *Brca1*^Δ11/Δ11^ and *Blm*^Δ/Δ^ cells did not show substantial differences in CSR, the rate of switching was markedly reduced in *Trp53bp1*^−/−^ cells (Fig. S3, A and B). Interestingly, the increased accumulation of 53BP1 in *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ B cells relative to *Brca1*^Δ11/Δ11^ cells was sufficient to impact the efficiency of CSR. On the other hand, we did not observe any substantial defects in the accumulation of RPA at sites of IR--induced damage in any of the genotypes used ([Fig. 5, E and F](#fig5){ref-type="fig"}; and Fig. S3, C and D). These results show that although deletion of *Brca1* or *Blm* can impact 53BP1 recruitment, this effect does not substantially alter DSB resection, as revealed by RPA accumulation. The difference in HR efficiency between *Brca1*^Δ11/Δ11^ and *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ cells is therefore likely to be dependent on a subsequent step in the HR pathway, when RAD51 is loaded.

Rescue of RAD51 foci formation and HR in BRCA2- and XRCC2-deficient cells by silencing of *BLM* {#s06}
-----------------------------------------------------------------------------------------------

Efficient HR is dependent on several factors that contribute to accumulation of RAD51 at resected DSBs. These include PALB2 (partner and localizer of BRCA2), BRCA2, and XRCC2 ([@bib38]; [@bib57]; [@bib75]; [@bib37]). To further dissect the mechanism by which BLM coordinates HR, we knocked down each of these factors individually, and in combination with siBLM oligonucleotides (Fig. S4, A--C). Interestingly, ablation of *BLM* was sufficient to rescue RAD51 foci formation in cells treated with either siBRCA2 or siXRCC2 oligos ([Fig. 6 A](#fig6){ref-type="fig"}). This result suggests that BLM has a general role in reversing RAD51 nucleoprotein filament formation, which can be revealed in cells lacking key HR factors. Loss of RAD51 foci in siPALB2 cells was not rescued by ablation of *BLM*, suggesting that PALB2 may have a distinct role in RAD51 recruitment. To validate the importance of BLM depletion after silencing of *BRCA2* or *XRCC2*, we used EJ-DR cells to measure HR efficiency. Consistent with the immunofluorescence measurements of RAD51 foci, HR was rescued in both siBRCA2 and siXRCC2 cells after codepletion of BLM ([Fig. 6 B](#fig6){ref-type="fig"}).

![**Rescue of RAD51 IRIF and HR in BRCA2- and XRCC2-deficient cells by silencing of *BLM* requires BLM helicase activity, but not TOP3A.** (A) Quantification of RAD51 IRIF in U2OS cells after indicated knockdowns and IR. (B) Analysis of relative HR frequency in the U2OS EJ-DR reporter cell line after indicated knockdown. (C) Western blot analysis of *TOP3A* knockdown efficiency in U2OS cells with no treatment (NT) and indicated siRNA-mediated knockdowns. (D) Quantification of RAD51 IRIF in U2OS cells after indicated knockdowns and IR. (E) Analysis of relative HR frequency in the U2OS EJ-DR reporter cell line after indicated knockdowns. Graphs represent mean ± SD of three independent experiments.](JCB_201703144_Fig6){#fig6}

In separate experiments, we found that knockdown of *TOP3A* did not afford a similar rescue phenotype as was seen with siBLM ([Fig. 6, C and D](#fig6){ref-type="fig"}), again suggesting that the ability of BLM to regulate RAD51 stability is likely to be independent of the BTR complex. The helicase activity of BLM appears to influence HR in siBRCA2 cells, however. Expression of exogenous BLM^WT^ in siBRCA2 cells reversed the rescue of HR that was achieved by knockdown of *BLM*, but an equivalent effect was not observed upon expression of the helicase-dead BLM^K695A^ mutant ([Fig. 6 E](#fig6){ref-type="fig"}). Collectively with our other data ([Fig. 4 F](#fig4){ref-type="fig"}), this result suggests that the helicase activity of BLM is essential for its anti-recombinase effect in cells of several different genetic backgrounds.

Several enzymes have been reported to exhibit anti-recombinase activity in mammalian cells ([@bib39]). We performed siRNA knockdown of three of these factors to evaluate if they could rescue HR in cells lacking BRCA2 or XRCC2 (Fig. S5, A--C). First, we tested the RECQ5/*RECQL5* helicase, which is reported to have anti-recombinase activity ([@bib34]). Although *BLM* knockdown can partially rescue the defect in RAD51 foci and HR in cells treated with siBRCA2 or siXRCC2 ([Fig. 6, A and B](#fig6){ref-type="fig"}), equivalent knockdown of *RECQL5* had little effect ([Fig. 7, A and B](#fig7){ref-type="fig"}). FBH1 is a second protein that has been reported to act as a mammalian anti-recombinase, and WRN is a RECQ helicase that has been shown to target RAD51-loaded DNA structures ([@bib20]; [@bib25]; [@bib70]). To evaluate the effect of these factors on recombination efficiency, we repeated our HR assay in siBRCA2 and siXRCC2 cells with combined knockdown of either *FBH1* or *WRN* ([Fig. 7 C](#fig7){ref-type="fig"}). Knockdown of *WRN* or *FBH1* afforded a rescue of HR in siXRCC2 cells. Knockdown of *WRN* also gave a partial rescue of HR in siBRCA2 cells, but no significant difference in HR efficiency was observed in these cells upon knockdown of *FBH1*. The efficiency of NHEJ was not affected in any case ([Fig. 7 D](#fig7){ref-type="fig"}). We conclude that the ability of BLM to suppress HR is of an equivalent magnitude to that seen with other mammalian anti-recombinases, at least in cells that are HR deficient.

![**Effect of pro- and anti-recombinogenic proteins on HR efficiency.** (A) Quantification of RAD51 IRIF in U2OS cells after indicated knockdowns and IR. (B and C) Analysis of relative HR frequency in the EJ-DR U2OS reporter cell line after indicated knockdowns and *I-Sce1* induction. (D) Analysis of relative mutagenic NHEJ (mNHEJ) frequency in the EJ-DR U2OS reporter cell line after indicated knockdowns and *I-Sce1* induction. (E) Model for BLM acting as an anti-recombinogenic factor at the level of RAD51 loading to regulate efficient HR. Graphs represent mean ± SD of three independent experiments.](JCB_201703144_Fig7){#fig7}

Discussion {#s07}
==========

Regulation of HR through altered stability of the RAD51 nucleoprotein filament {#s08}
------------------------------------------------------------------------------

Our results show that BLM promotes genomic instability in HR-deficient cells, to a level that can cause cell death, by reducing the stability of RAD51 at the presynaptic filament. BLM appears to act by disrupting RAD51 on resected DNA ends. In WT cells, the presence of BRCA1, BRCA2, and factors including XRCC2 stabilizes the RAD51 nucleoprotein filament despite the anti-recombinogenic effect of BLM, but when these factors are absent, there is a failure to retain RAD51 at the break site that leads to insufficient HR, genomic instability, and loss of cell viability ([Fig. 7 E](#fig7){ref-type="fig"}). Hyperaccumulation of RAD51 at DNA damage sites in BS cells has been observed previously ([@bib8]; [@bib74]), and an ability of BLM to displace RAD51 from single-stranded DNA is supported by several lines of cellular and biochemical evidence ([@bib10]; [@bib66], [@bib67]). This work is the first to demonstrate that this activity has substantial physiological importance. This ability of BLM is distinct from proposed roles for the protein in DSB resection ([@bib27]; [@bib55], [@bib56]), D-loop displacement ([@bib68]; [@bib4]), or Holliday junction dissolution ([@bib73]).

Several cellular factors have been shown to maintain replication fork integrity by stabilizing RAD51 filaments ([@bib61]; [@bib43]; [@bib60]), and we find an equivalent role for BLM. Deletion of *Blm* largely rescues the fork degradation that is normally seen in *Brca1*^Δ11/Δ11^ cells ([Fig. 2, F and G](#fig2){ref-type="fig"}), suggesting that BLM influences both HR efficiency and fork protection by regulating RAD51 filament stability. Interestingly, silencing of *BLM* has been reported to help protect replication forks and maintain genomic integrity in cells lacking the replication-associated protein BOD1L ([@bib30]). Targeting the anti-recombinase activity of BLM may therefore rescue genomic integrity in an even greater range of genotypes than those that we have tested in this study.

BLM as an Srs2-like anti-recombinase {#s09}
------------------------------------

Like BLM, the DNA damage response factor 53BP1 also regulates the efficiency of HR, albeit by a different mechanism ([@bib9]; [@bib12]). 53BP1 limits DSB resection, thereby inhibiting HR and promoting use of alternative pathways for DSB repair such as NHEJ. The effect of BLM appears to be exerted at the level of stabilization of RAD51 on the resected 3′ single-stranded DNA region. This direct effect on RAD51 is reminiscent of the anti-recombinogenic effect of Srs2 during HR in *Saccharomyces cerevisiae.* Diploid yeast lacking Srs2 are hyperrecombinogenic and exhibit hypersensitivity to UV and IR, which can be rescued by mutations in RAD51 ([@bib1], [@bib2]). Srs2 stimulates the ATPase activity of RAD51 at resected DSBs, promoting release of RAD51, and limiting the formation of an active presynaptic filament ([@bib41]; [@bib69]). Previous biochemical work has shown that the K695A mutant of BLM, which lacks DNA translocase and helicase activity, is not able to displace RAD51 from DNA templates in vitro ([@bib10]). Our cell biological assays support the idea that the helicase activity of BLM is critical for its anti-recombinase function. Our work additionally shows that the association of BLM with topoisomerase IIIα, RMI-1, and RMI-2 as the BTR complex, which is essential for Holliday junction dissolution, is likely dispensable for its anti-recombinase activity.

BLM is one of a group of mammalian anti-recombinases {#s10}
----------------------------------------------------

Although no precise mammalian orthologue of Srs2 has been identified, several proteins have been suggested to have an analogous function. These include FBH1, RECQ5, PARI, and POLQ ([@bib34]; [@bib25]; [@bib62]; [@bib52]; [@bib63]; [@bib14]). It is not clear which of these proteins is of greatest importance for regulation of mammalian HR ([@bib40]). In our work, we measured the effect of ablation of BLM and the putative anti-recombinases, RECQ5, WRN, and FBH1 on the efficiency of HR in cells lacking key HR factors. We found that depletion of BLM has at least as significant an effect as depletion of these other putative anti-recombinases ([Fig. 7, A--C](#fig7){ref-type="fig"}). These results raise an important question of whether these factors act redundantly or are regulated to work in specific instances. Notably, BLM and RECQ5 act in a nonredundant fashion to suppress crossover recombination ([@bib71]; [@bib33]).

Effect of BLM on HR in BRCA2-, XRCC2-, and PALB2-deficient cells {#s11}
----------------------------------------------------------------

Whereas our overexpression analysis suggests that BLM works as an active anti-recombinase in normal cells, the effects of the absence of the anti-recombinase activity of BLM was most easily observed in cells with deficiencies in HR. In addition to its effect in *Brca1*^Δ11/Δ11^ cells, deletion of *BLM* afforded some degree of rescue of the HR defect normally seen in siBRCA2 and siXRCC2 cells. Deletion of *BLM* did not, however, afford any substantial rescue of HR in PALB2-deficient cells. This result was unexpected, because PALB2 interacts with both BRCA1 and BRCA2 to allow stable association of BRCA2 at DSB sites and loading of RAD51 ([@bib75]; [@bib65]; [@bib77]). As PALB2 deficiency is not rescued by *BLM* deletion, it is possible that PALB2 plays a role separate from BRCA1 and BRCA2 in the control of genomic integrity or RAD51 loading. Notably, PALB2 has been shown to directly interact with D-loop structures, where it is able to interact with and stabilize RAD51 ([@bib11]). PALB2 also binds MRG15, a chromodomain protein that modifies the efficiency of HR ([@bib64]). Clearly, the full range of activities that regulate the stability of the RAD51 nucleoprotein filament warrants further study.

Our results support a hypothesis in which a failure to constrain mutagenic RAD51-dependent processes such as nonallelic HR may lead to the chromosome instability seen in BS cells ([@bib5]; [@bib13]). *SGS1*, the yeast homologue of *BLM*, suppresses recombination between homologous sequences and can partially substitute for Srs2 in *srs2* mutant yeast ([@bib54]; [@bib49]; [@bib36]). Deletion of *Blm* in mouse spermatocytes also leads to a block in meiosis associated with mispairing of homologous chromosomes and increased chiasmata ([@bib31]). We propose that BLM deserves further consideration as an anti-recombinase with substantial importance in regulating the HR pathway for repair of mammalian DSBs.

Materials and methods {#s12}
=====================

Cell culture {#s13}
------------

Resting primary B cells were isolated from mouse spleen by ACK lysis of erythrocytes and negative selection with anti-CD43 MACS microbeads (Miltenyi). B cells were resuspended at 0.5--1 × 10^6^ cells/ml and activated with 25 µg/ml lipopolysaccharide (L2630; Sigma Aldrich), 50 U/ml IL-4 (I1020; Sigma Aldrich), and 1:1,000 RP105 antibody (55128; BD) for 48--72 h. MEFs as well as U2OS, MDA-MB-231, and MDA-MB-436 cells were cultured in DMEM supplemented with 15% FBS and 1% penicillin/streptomycin.

DNA repair assay {#s14}
----------------

The EJ-DR assay was performed as previously described ([@bib7]). EJ-DR reporter cells were plated at 200,000--500,000 cells per well in 10% charcoal-stripped FBS (100--119; Gemini), antibiotic/antimycotic, and DMEM and transfected the next day with siRNA and/or plasmid DNA using Lipofectamine 2000 (11668; Invitrogen) or Lipofectamine RNAiMAX (13778; Invitrogen). After knockdown and expression (24 h), cells were grown in 10% Tet-free FBS (100-800; Gemini), antibiotic/antimycotic, and DMEM. Incorporated *I-Sce1* was induced with Shield1 (632189; Clontech) and triamcinolone (T6510; Sigma Aldrich) ligands for 24 h. NHEJ and HR repair activity was assessed 48 h postinduction by quantification of DsRed- and GFP-positive cells on BD FACS Calibur system and analyzed on FlowJo (Tree Star).

Metaphase spreads {#s15}
-----------------

Telomere DNA FISH analysis was performed and analyzed as previously described ([@bib51]). B cells were activated for 24 h and treated with 250 nM mitomycin C (Sigma Aldrich), 2 µM olaparib (KU0059436; Selleckchem), or 4 µM cisplatin (Sigma Aldrich) for 16 h. Cells were arrested in metaphase with 100 ng/ml colcemid (Sigma Aldrich) for 1 h. Cells were collected, incubated in hypotonic solution (0.075 M KCl) for 15 min at 37°C, and fixed in a 3:1 methanol/acetic acid solution (three washes) and stored overnight at −20°C. Cells were dropped onto glass microscope slides in a Thermotron at 52% humidity at 22.9°C and dried for 30 min to 1 h and stored in 37°C chamber. Telomere DNA FISH analysis was performed by first preparing the telomeric Cy-3 PNA probe (Cy3-00-CCCTAACCCTAACCCTAA, F1002; PNA Bio Inc.). The probe was incubated in deionized formamide, pH 7.0, at 37°C for 1 h, followed by addition of FISH Master Mix (4× SSC, 20% dextran sulfate) and incubation in at 37°C for 1 h. Probe was denatured at 80°C followed by preannealing at 37°C for 1 h.

Concurrently, chromosome slides were pretreated with pepsin in 0.01 M HCl acidic solution for 90 s at 37°C, followed by washes in 1× PBS and 1× PBS/50 mM MgCl~2~, and fixed in 1% formaldehyde/1× PBS/50 mM MgCl~2~ for 10 min. Slides were then washed in 1× PBS, dehydrated in a series of ethanol incubations (70%, 90%, and 100%), and air dried. Slides were denatured by incubation at 80°C in 70% deionized formamide/2× SSC for 90 s, followed by dehydration in a series of ethanol incubations (70%, 90%, and 100%), and air dried. In a humidity chamber, the preannealed probe mix was applied to the slide, covered with 18 × 18 mm coverslip, and incubated for 1 h at 37°C. The probe was cross-linked in 50% formamide/2× SSC (three 5-min washes), followed by washes in 1× SSC (3 × 5 min washes) and 1× SSC/0.1% Tween 20 (three 5-min washes). Slides were counterstained in DAPI solution, washed in 3× SSC, and mounted in Mowiol antifade solution. For each experiment, 50 metaphases per genotype and treatment were analyzed.

Animal husbandry {#s16}
----------------

All animal experiments were approved by the Institutional Animal Care and Use Committee at Rutgers University (protocol 12--024).

Flow cytometry {#s17}
--------------

Primary T cells were isolated from thymi of 2- to 3-mo-old mice in 1× HBSS, 1% FBS/1× penicillin/streptomycin and strained through a 70-μm mesh. Blocking was with anti--CD16/CD32 antibody (rat, 553142; BD Biosciences) and stained with APC-CD8a (rat; 553035; BD Biosciences) and/or FITC-CD4 (rat, 553046; BD Biosciences) antibodies. For analysis of CSR, B cells were stained with 1:100 dilutions of anti-B220-FITC (rat; 553088, BD Biosciences) and biotin anti--mouse IgG1 (rat, 553441; BD) followed by incubation in streptavidin Alexa Fluor 647 ([S32357](S32357); Thermo Fisher). Cells were washed twice in 1× HBSS, 1% FBS, and 1× penicillin/streptomycin. For analysis of RPA staining, B cells treated with 10 Gy IR followed by 2 h of recovery were extracted with PBS with Tween 20, fixed in 4% PFA, permeabilized, and stained with RPA32 antibody (rat, 1:500, 2208; Cell Signaling). After secondary staining with Alexa Flour 488 anti-rat (1:200; [A11006](A11006); Life Technologies), cells were stained for DNA content using propidium iodide ([@bib24]). Flow cytometry analysis was performed on BD FACSCalibur system and analyzed on FlowJo (Tree Star).

Sister chromatid exchange assay {#s18}
-------------------------------

B cells were activated in the presence of 10 μm BrdU for 48 h followed by arrest in metaphase with 100 ng/ml colcemid (Sigma Aldrich). Cells were fixed and dropped onto glass slides for metaphase spreads (see Materials and Methods). Slides were stained with Hoechst 33258 (Thermo Fisher), incubated in McIlvaine's solution (164 mM Na~2~HPO~4~, 16 mM citric acid, pH 7.0), and exposed to UV light for 45 min. Slides were incubated in a 1:12 Giemsa staining solution in 3% methanol, dehydrated with xylenes, and mounted with Permount (Fisher Scientific).

DNA combing {#s19}
-----------

Splenic B cells were grown in vitro for 48 h under activating conditions. Cells were incubated with 25 µM 5-iododeoxyuridine (I7125; Sigma Aldrich) for 20 min followed by a 20 min incubation with 250 µM 5-chlorodeoxyuridine (C6891; Sigma Aldrich). Cells were subsequently treated with 4mM hydroxyurea for five hours (H8627; Sigma Aldrich). DNA fiber spreads were prepared and analyzed by immunofluorescence as previously described ([@bib44]). Cell suspension was collected in 2-µl volume and dried on glass slide. Cells were lysed in 7 μl lysis buffer consisting of 50 mM EDTA and 0.5% SDS in 200 mM Tris-HCl, pH 7.5, for 2 min. Slides were tilted at 15° angle to dry and create spread of DNA fibers. Slides were fixed in methanol/acetic acid solution (3:1) for 10 min followed by incubation in 2.5M HCl for 80 min. Slides were washed with PBS, blocked in 5% BSA for 20 min, and stained with 1:25 anti-BrdU (mouse) and 1:400 anti-BrdU (rat) in 5% BSA for 2 h in a humidity chamber. Slides were washed with PBS and stained with 1:500 sheep anti--mouse Cy3 and 1:400 goat anti--rat Alexa Fluor 488 secondary antibody for 1 h. Slides were again washed in PBS and mounted using Vectashield mounting medium with glass coverslips. Approximately 300 fiber lengths were analyzed per genotype in three independent experiments using ImageJ software.

Western blotting and immunofluorescence {#s20}
---------------------------------------

Primary antibodies were used at the following dilutions for Western blotting: anti-tubulin (mouse, 1:50,000; Sigma Aldrich), mouse anti-BLM (rabbit, 1:1,000; A300-110A; Bethyl), human anti-BLM (rabbit, 1:1,000; ab2179; Abcam), anti-BRCA1 (mouse, 1:1,000; MABC199; EMD Millipore), anti-RECQ5 (rabbit, 1:1,000; ab31609; Abcam), anti-TOP3A (rabbit, 1:2,000; 14525-1-AP; Proteintech), anti-XRCC2 (mouse, 1:1,000; ab20253; Abcam), anti-BRCA2 (rabbit, 1:1,000; sc28235; Santa Cruz), anti-WRN (mouse, 1:500; ab66606; Abcam), anti-FBH1 (mouse, 1:1,000; sc-81563; Santa Cruz), and anti-PALB2 (1:1,000, M11, raised in rabbits against amino acids 601--880 of human PALB2). Secondary HRP-conjugated anti--mouse (sheep; 1:2,000; NA931V; GE Healthcare) and anti--mouse (donkey; 1:2,000; NA9340V; GE Healthcare) antibodies were used.

For immunofluorescence, U2OS, MEF, and MDA-231/436 cells were grown on 18 × 18-mm coverslips overnight before 10 Gy IR treatment and 2-h recovery. B lymphocyte cells were activated and treated with 10 Gy IR and 4 h recovery before being dropped onto slides coated with Cell-tak (BD). Cells were preextracted in 0.5% Triton X-100 in PBS, fixed in 2% paraformaldehyde in PBS, and permeabilized in 0.5% Triton X-100 in PBS and incubated in antibody. Primary antibodies were used at the following dilutions: anti-RAD51 (rabbit, 1:100; H-92; Santa Cruz), anti-53BP1 (rabbit, 1:2,000; NB100-304; Novus), and anti-RPA32 (rat, 1:100; 2208; Cell Signaling) and detected with anti--rabbit Alexa Fluor 546 or Alexa Fluor 488 antibody (1:200; Thermo Fisher) or anti--rat Alexa Fluor 488 (1:200; Life Technologies). Cells were counterstained with DAPI and mounted in Mowiol solution. Approximately 200--500 cells per treatment were analyzed for each experiment.

Plasmids {#s21}
--------

The BRCA1 expression constructs were based on pcDNA-3xMyc-BRCA1, which was provided by B. Xia (Rutgers Cancer Institute of New Jersey, New Brunswick, NJ) and has been previously described ([@bib17]; [@bib3]). The BRCA1^Δ11^ construct was generated through site-directed mutagenesis following the QuikChange protocol (Agilent Technologies).

The full-length *hBLM* was PCR amplified from the pGFP-C1-BLM (80070; Addgene), provided by N. Ellis (The University of Arizona Cancer Center, Tuscon, AZ; [@bib32]), using the iPROOF High-Fidelity PCR kit (Bio-Rad) and a 3′ primer (5′-TGCT TTAATTAATTACTTGTCGTCATCGTCCTTGTAGTCTGAGAATGCATATGAAGGCTTAAGAAACGGTCTATT-3′) containing codons for the FLAG epitope tag (DYKDDDDK). The amplified product was ligated into the pMx-GFP vector by restriction digest with Xho1 and Pac1 to generate the pMx-GFP-hBLMFLAG construct. The BLM^K695A^ construct was generated through site-directed mutagenesis following the QuikChange protocol (Agilent Technologies).

siRNA and shRNA {#s22}
---------------

For depletion of *BLM* by shRNA, a pLKO.1 plasmid containing the targeting sequence (5′-CCGGCGAAGGAAACTCACGTCAATACTCGAGTATTGACGTGAGTTTCCTTCGTTTTTG-3′; TRCN0000070996; Sigma Aldrich) for MEFs, a pLKO.1 plasmid containing the targeting sequence (5′-GCCTTTATTCAATACCCATTT-3′; TRCN0000004904; Sigma Aldrich) for human cells, or control vector was transfected into 293T cells with pMD2.G and pVSVG plasmids to produce lentivirus. MEF cells were infected with lentivirus and selected in medium containing 2 µg/ml puromycin for 1 wk and maintained in 1 µg/ml puromycin thereafter. For transient knockdown via siRNA, siGENOME SMARTpool constructs targeting BLM, BRCA2, XRCC2, PALB2, TOP3A, RecQ5, FBH1, and WRN were acquired commercially (Dharmacon; Table S1) and transfected into U2OS and U2OS EJ-DR reporter cell lines. Custom siRNAs targeting the 3′-UTR region of *BRCA1* and *BLM* were used for knockdown and mutant expression experiments (Table S2). Knockdown efficiency was confirmed via Western blot analysis.

Microscopy {#s23}
----------

Metaphase spreads were mounted in Mowiol solution and imaged at room temperature using an AxioImager.Z2 microscope (Zeiss) with a Plan-Apo 60×/1.4 oil objective lens (Nikon). The microscope was fitted with a CoolCube 1m camera system and MetaSystems Metafer automatic slide platform. Acquisition of images was performed using Metafer4 v3.9.6 software and images were viewed in Photoshop CS6 (Adobe). Immunofluorescence slides were mounted in Mowiol solution and imaged at room temperature using an E800 microscope (Nikon) with anApochromat 63×/1.4 oil objective lens (Zeiss). The microscope was fitted with a DXM1200F camera system (Nikon). Acquisition of images was performed using ACT-1 software (Nikon) and viewed and overlaid in PhotoShop CS6.

Statistical analysis {#s24}
--------------------

All experiments were performed with a minimum of three independent experiments. Data and statistical analysis was performed on GraphPad Prism 6. Error bars represent standard deviation between experiments. P-values were calculated using a Student's *t* test.

Online supplemental material {#s25}
----------------------------

Fig. S1 shows that ablation of *Blm* rescues genomic instability in *Brca1^Δ11/Δ11^* cells. Fig. S2 shows an analysis of SCEs in *Brca1*^Δ11/Δ11^*;Blm*^Δ/Δ^ cells and BLM overexpression and Rad51 foci in U2OS cells. Fig. S3 shows that ablation of *Blm* increases CSR in *Brca1*^Δ11/Δ11^ cells but has no effect on RPA intensity. Fig. S4 shows knockdown of *PALB2*, *BRCA2*, and *XRCC2* in U2OS cells. Fig. S5 shows knockdown of *RECQ5*, *FBH1*, and *WRN* anti-recombination factors in U2OS cells. Table S1 lists the Dharmacon siRNA oligonucleotides used. Table S2 lists the custom siRNA oligos used.
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